1. Nahon KJ, Doornink F, Straat ME, Botani K. Effect of sitagliptin on energy metabolism and brown adipose tissue in overweight individuals with prediabetes: a randomized placebo-controlled trial. Diabeto 2018; 61(11):2386-2397.
2. Cereijo R, Giralt M, Villarroya F. Thermogenic brown and beige/brite adipogenesis in humans. Ann. Med 2015; 47:169–177.
3. Montanari T, Poscic N, Colitti M. Factors involved in white-to-brown adipose tissue conversion and in thermogenesis: a review. Obes Rev 2017; 18(5):495-513.
4. Villarroya F., Vidal-Puig A. Beyond the sympathetic tone: The new brown fat activators. Cell Metab 2013; 17:638–643.
5. Martinez IY, Camarillo ED, Garduno JJ. Irisin a novel metabolic biomarker: present knowledge and future directions. Int J Endocrinol 2018; 20:78-85.
6. Pedersen B.K. Exercise-induced myokines and their role in chronic diseases. Brain Behav. Immun 2011; 25:811–816.
7. Norheim F., Langleite T. M., Hjorth M. The effects of acute and chronic exercise on PGC-1α, irisin and browning of subcutaneous adipose tissue in humans. FEBS Journal 2014; 281(3):739–749.
8. Hecksteden A., Wegmann M., Steffen A. Irisin and exercise training in humans—results from a randomized controlled training trial. BMC Medicine 2013; 11:235-41.
9. Kartinah N, Sianipar I. The effects of exercise regimens on irisin levels in obese rat's model: comparing high-intensity intermittent with continuous moderate-intensity training. Biomed Res Int 2018; 2018:4708287-11.
10. Tibana R, da Cunha Nascimento D, Frade de Souza N. Irisin levels are not associated to resistance training-induced alterations in body mass composition in older untrained women with and without obesity. The Journal of Nutrition, Health & Aging 2017; 21(3):241–246.
11. Huh Y, Siopi A, Mougios V, Park K. H, Mantzoros S. Irisin in response to exercise in humans with and without metabolic syndrome. The J of Clin Endo & Metab 2015; 100(3):453–457.
12. Wang H, Du L, Wu T, Yang G. Circulating betatrophin is associated with insulin resistance in humans: cross-sectional and interventional studies in vivo and in vitro. Onco 2017; 8(57):96604-96614.
13. Yi P, Park J, Melton D. Betatrophin: a hormone that controls pancreatic β cell proliferation. Cell 2013; 153(4):747-58.
14. Abu-Farha M, Al-Khairi I, Cherian P, Chandy B. Increased ANGPTL3, 4 and ANGPTL8/betatrophin expression levels in obesity and T2D. Lipids Health Dis 2016; 15(1):181.
15. Wang H, Lai Y, Han C, Liu A, Fan C. The effects of serum ANGPTL8/betatrophin on the risk of developing the metabolic syndrome – A Prospective Study. Sci Rep 2016; 6:28431-37.
16. Crujeiras A, Zulet M, Abete I, Amil M. Interplay of atherogenic factors, protein intake and betatrophin levels in obese-metabolic syndrome patients treated with hypocaloric diets. Int J Obes 2016; 40(3):403-10.
17. Enteshari M, Esfarjani F, Reisi J. Comparison of the effects of two different intensities of combined training on irisin, betatrophin, and insulin levels in women with type 2 diabetes. Asian J Sports Med 2019; 10(2):68943-9.
18. Coqueiro R, Soares T, Pereira R. Therapeutic and preventive effects of exercise on cardiometabolic parameters in aging and obese rats. Clin Nutr ESPEN 2019; 29:203-212.
19. Xie X, Gao T, Yang M, Chen P, Jin H, Yang L, Yu X. Associations of betatrophin levels with irisin in Chinese women with normal glucose tolerance. Diabetol Metab Syndr 2015; 7:26-32.
20. Malafaia AB, Nassif PA, Ribas CA, Ariede BL. Obesity induction with high fat sucrose in rats. Arq Bras Cir Dig 2013; 26: 17-21.
21. Shirvani H, Delpasand A, Bazgir B. The data on the aerobic training with or without calorie restriction and muscular levels of Irisin and muscular FNDC5 concentration in obese male Wistar rats. Data Brief 2018; 21:888-892.
22. Ghasemi H, Tavilani H, Khodadadi I, Saidijam M, Karimi J. Circulating betatrophin levels are associated with the lipid profile in type 2 diabetes. Chonnam Med J 2015; 51(3):115-9.
23. Wang Y, Quagliarini F, Gusarova V, Gromada J. Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. Proc Natl Acad Sci USA 2013; 110(40):16109-14.
24. Gómez J, Pascual E, Catalán V. Circulating betatrophin concentrations are decreased in human obesity and type 2 diabetes. J Clin Endocrinol Metab 2014; 99(10):2004-9.
25. Liu D, Li S, He H, Yu C, Li X, Liang L. Increased circulating full-length betatrophin levels in drug-naïve metabolic syndrome. Onco 2017; 8(11):17510-17517.
26. Miyamoto E, Sato K, Kurihara T. Endurance training-induced increase in circulating irisin levels is associated with reduction of abdominal visceral fat in middle-aged and older adults. PloS One 2015; 10(3):0120354-60.
27. Dunnwald T, Melmer A, Gatterer H, Salzmann K. Supervised short-term high-intensity training on plasma irisin concentrations in type 2 diabetic patients. Int J Sports Med 2019; 31:4-9.
28. Lu Y, Li H, Shen SW, Shen ZH, Xu M. Swimming exercise increases serum irisin level and reduces body fat mass in high-fat-diet fed Wistar rats. Lipids Health Dis 2016; 15:93-99.
29. Ghaderi M, Mohebbi H , Soltani B. The effect of 14 weeks of endurance training with two different Intensity on serum irisin level, gene expression of skeletal muscle PGC1-α and FNDC5 and subcutaneous adipose tissue UCP1 in obese rats. Med J Tabriz Uni Med Sciences Health Services 2019; 41(1):72-81. [Persian]
30. Ghaderi M, Mohebbi H, Soltani B. The Effect of 14 Weeks of Endurance Training with Two different Intensity on Serum Irisin Level, Gene Expression of Skeletal Muscle PGC1-α and FNDC5 and Subcutaneous Adipose Tissue UCP1 in Obese Rats. Med J Tabriz Uni Med Sciences Health Services. 2019;41(1):72-81. [Persian]
31. Boström P, Wu J, Jedrychowski MP, Korde A. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481(7382):463-8.
32. Fatouros IG. Is irisin the new player in exercise-induced adaptations or not? A 2017 update. Clin Chem Lab Med 2018; 56(4):525-548.
33. Su X, Xu J, Zheng C. The relationship between non-alcoholic fatty liver and skeletal muscle mass to visceral fat area ratio in women with type 2 diabetes. BMC Endocr Disord 2019; 19(1):76-82.